Monitoring & aggressive treatment of lung disease during early childhood are critical to improving outcomes in CF. Yet, clear & convincing evidence-based data to guide optimal clinical care in young children with CF are lacking. This symposium will utilize a pro-con style debate to address three controversial topics in early CF lung disease (<6 years of age).
Describe the evidence for & against the use of surveillance lung function testing to assess & monitor early CF lung disease.
Identify the risks & benefits of surveillance bronchoscopy to assess early CF lung disease.
Discuss the risks, benefits & evidence of early aggressive Staphylococcus aureus prevention & treatment in infants & young children with CF.
Professor of Pediatric Pulmonary Medicine,
University of Arizona--Banner University Med Cent